Quantum Biopharma Ltd. (CVE:QNT – Free Report) – Analysts at Singular Research issued their Q1 2026 earnings estimates for shares of Quantum Biopharma in a research note issued to investors on Wednesday, June 18th. Singular Research analyst G. Sriharan forecasts that the company will post earnings per share of ($0.10) for the quarter. Singular Research has a “Moderate Buy” rating on the stock. Singular Research also issued estimates for Quantum Biopharma’s Q2 2026 earnings at ($0.27) EPS, Q3 2026 earnings at ($0.48) EPS and Q4 2026 earnings at ($0.73) EPS.
Quantum Biopharma Stock Performance
Insider Transactions at Quantum Biopharma
In related news, Senior Officer Nathan Patrick Coyle sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of C$20.16, for a total transaction of C$60,480.00.
Featured Stories
- Five stocks we like better than Quantum Biopharma
- What is a Stock Market Index and How Do You Use Them?
- 3 Hot Trades for Insiders, But Are They Good Buys for Investors?
- The How And Why of Investing in Oil Stocks
- Why Qualcomm’s Latest Price Target Can’t Be Ignored
- Most Volatile Stocks, What Investors Need to Know
- Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs
Receive News & Ratings for Quantum Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
